Background: Upper gastrointestinal disorders typically present with common symptoms. The most relevant non-mucosal diseases are gastroparesis, functional dyspepsia and rumination syndrome. The literature pertaining to these 3 conditions was reviewed. Key Messages: Gastroparesis is characterized by delayed gastric emptying in the absence of mechanical obstruction of the stomach. The cardinal symptoms include postprandial fullness (early satiety), nausea, vomiting and bloating. The most frequently encountered causes of these symptoms are mechanical obstruction (pyloric stenosis), iatrogenic disease, gastroparesis, functional dyspepsia, cyclical vomiting and rumination syndrome. The most common causes of gastroparesis are neuropathic disorders such as diabetes, idiopathic, post-vagotomy and scleroderma among myopathic disorders. Principles of management of gastroparesis include exclusion of mechanical obstruction with imaging and iatrogenic causes with careful medication and past surgical history. Prokinetics and anti-emetics are the mainstays of treatment. Functional dyspepsia is characterized by the same symptoms as gastroparesis; in addition to delayed gastric emptying, pathophysiological abnormalities include accelerated gastric emptying, impaired gastric accommodation and gastric or duodenal hypersensitivity to distension and nutrients. Novel treatments include tricyclic antidepressants in patients with normal gastric emptying, acotiamide (acetyl cholinesterase inhibitor) and 5-HT1A receptor agonists such as buspirone. Rumination syndrome is characterized by repetitive regurgitation of gastric contents occurring within minutes after a meal. Episodes often persist for 1-2 h after the meal, and the regurgitant consists of partially digested food that is recognizable in its taste. Regurgitation is typically effortless or preceded by a sensation of belching. This has been summarized as a ‘meal in, meal out, day in, day out' behavior for weeks or months, differentiating rumination from gastroparesis. Patients often have a background of psychological disorder or a prior eating disorder. Treatment is based on behavioral modification. Conclusion: Precise identification of the cause and pathophysiology of upper gastrointestinal symptoms is essential for optimal management.

1.
Vella A, Bock G, Giesler PD, Burton DB, Foley JE, Rizza RA, Camilleri M: Effect of a dipeptidyl peptidase 4 (DPP-4) inhibitor, vildagliptin, on gastrointestinal function, nutrient intake and glucose metabolism in type 2 diabetes. Neurogastroenterol Motil 2007;19:434.
2.
Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL: The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. Aliment Pharmacol Ther 2012;36:379-390.
3.
Wu T, Ma J, Bound MJ, Checklin H, Deacon CF, Jones KL, Horowitz M, Rayner CK: Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. Diabetes 2014;63:2776-2787.
4.
Maes BD, Vanwalleghem J, Kuypers D, Ghoos Y, Rutgeerts PJ, Vanrenterghem YF: Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. Transplantation 1999;68:1482-1485.
5.
Maes BD, Evenepoel P, Kuypers D, Geypens B, Ghoos Y, Vanrenterghem Y: Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. Clin Transplant 2003;17:171-176.
6.
Jeong ID, Camilleri M, Shin A, Iturrino J, Boldingh A, Busciglio I, Burton D, Ryks M, Rhoten D, Zinsmeister AR: A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans. Aliment Pharmacol Ther 2012;35:1088-1096.
7.
Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V: Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-1479.
8.
Janssen P, Harris MS, Jones M, Masaoka T, Farré R, Törnblom H, Van Oudenhove L, Simrén M, Tack J: The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol 2013;108:1382-1391.
9.
Tack J, Bisschops R, Sarnelli G: Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127:1239-1255.
10.
Corinaldesi R, Stanghellini V, Raiti C, Rea E, Salgemini R, Barbara L: Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987;28:300-305.
11.
Jian R, Ducrot F, Ruskone A, Chaussade S, Rambaud JC, Modigliani R, Rain JD, Bernier JJ: Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci 1989;34:657-664.
12.
Lembo A, Camilleri M, McCallum RW, Sastre RF, Breton CF, Spence SC, White J, Gottesdiener K, Stoner E: A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of RM-131 in patients with diabetic gastroparesis. Gastroenterology 2014;146(suppl 1):S158-S159.
13.
Kusunoki H, Haruma K, Manabe N, Imamura H, Kamada T, Shiotani A, Hata J, Sugioka H, Saito Y, Kato H, Tack J: Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil 2012;24:540-545, e250-e251.
14.
Tack J, Janssen P, Masaoka T, Farré R, Van Oudenhove L: Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012;10:1239-1245.
15.
Kolar GJ, Camilleri M, Burton D, Nadeau A, Zinsmeister AR: Prevalence of colonic motor or evacuation disorders in patients presenting with chronic nausea and vomiting evaluated by a single gastroenterologist in a tertiary referral practice. Neurogastroenterol Motil 2014;26:131-138.
16.
Camilleri M, Shin A: Novel and validated approaches for gastric emptying scintigraphy in patients with suspected gastroparesis. Dig Dis Sci 2013;58:1813-1815.
17.
Szarka LA, Camilleri M, Vella A, Burton D, Baxter K, Simonson J, Zinsmeister AR: A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol 2008;6:635-643.e1.
18.
Camilleri M, Iturrino J, Bharucha AE, Burton D, Shin A, Jeong ID, Zinsmeister AR: Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants. Neurogastroenterol Motil 2012;24:1076-e562.
19.
Odunsi ST, Camilleri M, Szarka LA, Zinsmeister AR: Optimizing analysis of stable isotope breath tests to estimate gastric emptying of solids. Neurogastroenterol Motil 2009;21:706-e38.
20.
Bredenoord AJ, Chial HJ, Camilleri M, et al: Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003;1:264-272.
21.
Bharucha AE, Camilleri M, Forstrom LA, Zinsmeister AR: Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol (Oxf) 2009;70:415-420.
22.
Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998;115:1346-1352.
23.
Bouras EP, Delgado-Aros S, Camilleri M, Castillo EJ, Burton DD, Thomforde GM, Chial HJ: SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 2002;51:781-786.
24.
Tack J, Caenepeel P, Piessevaux H, Cuomo R, Janssens J: Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia. Gut 2003;52:1271-1277.
25.
Sarnelli G, Vos R, Cuomo R, Janssens J, Tack J: Reproducibility of gastric barostat studies in healthy controls and in dyspeptic patients. Am J Gastroenterol 2001;96:1047-1053.
26.
Breen M, Camilleri M, Burton D, Zinsmeister AR: Performance characteristics of the measurement of gastric volume using single photon emission computed tomography. Neurogastroenterol Motil 2011;23:308-315.
27.
Janssen P, Verschueren S, Ly HG, Vos R, Van Oudenhove L, Tack J: Intragastric pressure during food intake: a physiological and minimally invasive method to assess gastric accommodation. Neurogastroenterol Motil 2011;23:316-322, e153-e154.
28.
Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J: Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001;121:526-535.
29.
Kumar A, Attaluri A, Hashmi S, Schulze KS, Rao SS: Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol Motil 2008;20:635-642.
30.
Farré R, Vanheel H, Vanuytsel T, Masaoka T, Törnblom H, Simrén M, Van Oudenhove L, Tack JF: In functional dyspepsia, hypersensitivity to postprandial distention correlates with meal-related symptom severity. Gastroenterology 2013;145:566-573.
31.
Bharucha AE, Camilleri M, Burton DD, Thieke SL, Feuerhak KJ, Basu A, Zinsmeister AR: Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia. Am J Gastroenterol 2014;109:1910-1920; quiz 1909, 1921.
32.
O'Brien MD, Bruce BK, Camilleri M: The rumination syndrome: clinical features rather than manometric diagnosis. Gastroenterology 1995;108:1024-1029.
33.
Chial HJ, Camilleri M, Williams DE, Litzinger K, Perrault J: Rumination syndrome in children and adolescents: diagnosis, treatment, and prognosis. Pediatrics 2003;111:158-162.
34.
Wagaman JR, Williams DE, Camilleri M: Behavioral intervention for the treatment of rumination. J Pediatr Gastroenterol Nutr 1998;27:596-598.
35.
Thumshirn M, Camilleri M, Hanson RB, Williams DE, Schei AJ, Kammer PP: Gastric mechanosensory and lower esophageal sphincter function in rumination syndrome. Am J Physiol 1998;275(2 pt 1):G314-G321.
36.
Vijayvargiya P, Iturrino J, Camilleri M, Shin A, Vazquez-Roque M, Katzka DA, Snuggerud JR, Seime RJ: Novel association of rectal evacuation disorder and rumination syndrome: diagnosis, co-morbidities and treatment. United European Gastroenterol J 2014;2:38-46.
37.
Kim HS, Anderson JD, Saghafi O, Heard KJ, Monte AA: Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med 2015;22:694-699.
38.
Allen JH, de Moore GM, Heddle R, Twartz JC: Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004;53:1566-1570.
39.
Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology: Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013;108:18-37; quiz 38.
40.
Olausson EA, Störsrud S, Grundin H, Isaksson M, Attvall S, Simrén M: A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am J Gastroenterol 2014;109:375-385.
41.
Sanger GJ, Westaway SM, Barnes AA, Macpherson DT, Muir AI, Jarvie EM, Bolton VN, Cellek S, Näslund E, Hellström PM, Borman RA, Unsworth WP, Matthews KL, Lee K: GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil 2009;21:657-664, e30-e31.
42.
Leming S, Broad J, Cozens SJ, Otterson M, Winchester W, Lee K, Dukes GE, Sanger GJ: GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil 2011;23:958-e410.
43.
Broad J, Mukherjee S, Samadi M, Martin JE, Dukes GE, Sanger GJ: Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol 2012;167:763-774.
44.
Camilleri M, Papathanasopoulos A, Odunsi ST: Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2009;6:343-352.
45.
Van der Ploeg L, Laken H, Sharma S, Datta R, Halem H, Dong J, Touvay C, Teillot M, Noonan P, Tartaglia L, Stoner L, Henderson B, Gottesdiener K, Culler M: Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131. Life Sci 2014;109:20-29.
46.
Shin A, Camilleri M, Busciglio I, Burton D, Stoner E, Noonan P, Gottesdiener K, Smith SA, Vella A, Zinsmeister AR: Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2013;36:41-48.
47.
Shin A, Camilleri M, Busciglio I, Burton D, Smith SA, Vella A, Ryks M, Rhoten D, Zinsmeister AR: The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol 2013;11:1453-1459.e4.
48.
Marek GJ, Carpenter LL, McDougle CJ, Price LH: Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 2003;28:402-412.
49.
Yin J, Song J, Lei Y, Xu X, Chen JD: Prokinetic effects of mirtazapine on gastrointestinal transit. Am J Physiol Gastrointest Liver Physiol 2014;306:G796-G801.
50.
Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, Lacy BE, Müller-Lissner S, Quigley EM, Schuurkes J, De Maeyer JH, Stanghellini V: Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35:745-767.
51.
Shin A, Acosta A, Camilleri M, Boldingh A, Burton D, Ryks M, Rhoten D, Zinsmeister AR: A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol 2015;13:701-708.e1.
52.
McKinnell RM, Armstrong SR, Beattie DT, Fatheree PR, Long DD, Marquess DG, Shaw JP, Vickery RG: Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Bioorg Med Chem Lett 2013;23:4210-4215.
53.
Beattie DT, Armstrong SR, Vickery RG, Tsuruda PR, Campbell CB, Richardson C, McCullough JL, Daniels O, Kersey K, Li YP, Kim KH: The pharmacology of TD-8954, a potent and selective 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Front Pharmacol 2011;2:25.
54.
Chial HJ, Camilleri M, Burton D, Thomforde G, Olden KW, Stephens D: Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003;284:G130-G137.
55.
Van Oudenhove L, Kindt S, Vos R, Coulie B, Tack J: Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther 2008;28:1326-1333.
56.
Tack J, Masclee A, Heading R, Berstad A, Piessevaux H, Popiela T, Vandenberghe A, Kato H: A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009;21:272-280.
57.
Matsueda K, Hongo M, Tack J, Saito Y, Kato H: A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012;61:821-828.
58.
Miwa H, Nagahara A, Tominaga K, Yokoyama T, Sawada Y, Inoue K, Ashida K, Fukuchi T, Hojo M, Yamashita H, Tomita T, Hori K, Oshima T: Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104:2779-2787.
59.
Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, Lacy BE, DiBaise JK, Prather CM, Abraham BP, El-Serag HB, Moayyedi P, Herrick LM, Szarka LA, Camilleri M, Hamilton FA, Schleck CD, Tilkes KE, Zinsmeister AR: Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology 2015;149:340-349.e2.
60.
Camilleri M: Functional dyspepsia: mechanisms of symptom generation and appropriate management of patients. Gastroenterol Clin North Am 2007;36:649-664, xi-x.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.